Thrombi that form within lung vessels due to activation of platelets and inflammatory stimulation of the pulmonary vascular endothelium are a major cause of patient mortality and morbidity in many lung diseases, including acute lung injury. [1] [2] [3] [4] [5] Intense basic research efforts have provided new biological insights into the pathology of pulmonary thrombosis 2, 4, 6 ; however, development of new therapies that target thrombo-inflammatory mechanisms has been hampered by the lack of models and methods that permit analysis of the organ-level responses that underlie this lung condition in humans. Animal models of pulmonary microvascular thrombosis exist, but they do not mimic the altered hemostasis and hemodynamic complexity of human lungs. 7, 8 With animal models, it is also not possible to separate contributions of platelet-endothelial interactions vs. tissue-tissue (e.g., epithelial-endothelial) interactions that can contribute to development of thrombotic lesions in response to epithelial injury or inflammation induced by chemicals or mechanical injury. 9, 10 In addition, there is a critical need to develop in vitro disease models that can more effectively predict responses in humans because of ethical issues associated with animal testing. 11, 12 Although there are existing in vitro coagulation and platelet function assays, they do not incorporate physiological organ-level signaling between endothelial and parenchymal tissues, inflammatory activities, or relevant fluid hemodynamics, which are all key determinants of thrombosis. [13] [14] [15] [16] [17] [18] Due to these existing deficiencies, we explored whether microfluidic organ-on-a-chip (organ chip) technology 12, 19 can be used to address this challenge.
Human organs chips are microfluidic culture systems created with microchip manufacturing methods that contain hollow microchannels lined by living human cells that recapitulate organ-specific tissue-tissue interfaces and physical microenvironments (including fluid flow, air-liquid interfaces, and cyclic deformation in the case of the lungs) that are necessary to mimic human organ-level pathophysiology. 12 Here, we significantly modified a previously described human lung chip 20, 21 by replacing the established lung alveolar epithelial cell line (A549) originally isolated from a lung tumor 22 with primary human lung alveolar epithelial cells. We also lined all four walls of the second microchannel with human vascular endothelial cells to form a continuous endothelium-lined tube that enables human whole blood to be perfused through the chip instead of culture medium. This new primary human lung alveolus chip design enables whole human blood to be perfused through the vascular channel without producing thrombus formation under control conditions while allowing high resolution real-time analysis of interactions between human blood cells and endothelial cells in an organrelevant context. Using this technology in combination with novel analytical tools for quantitation of dynamic plateletendothelial interactions and clot formation, we demonstrate a key role of the epithelium in inflammation-driven vascular thrombosis during lipopolysaccharide (LPS) endotoxin-induced acute lung injury, and show that the model can be used to evaluate cytoprotective effects of a potential therapeutic with antithrombotic and anti-inflammatory activities in vitro.
RESULTS

Primary human lung alveolus chip
To develop an organ-level model of vascular inflammationinduced human pulmonary thrombosis in vitro that is also capable of dissection of intercellular communication, we modified a previously described lung chip microfluidic device that consists of two parallel rectangular microchannels separated by a thin, porous, flexible membrane coated with extracellular matrix (ECM). 20, 21, 23 First, we increased the microchannel dimensions of both the chambers in order to maximize the surface area exposed to blood and soluble factors. Then we covered all surfaces of the bottom microchannel with human umbilical vascular endothelial cells (HUVECs) in order to engineer a threedimensional (3D) microvessel that prevents contact of blood with the surrounding prothrombotic ECM-lined channel walls as occurs in living vessels (Figure 1a-c ; see METHODS for details). Finally, primary human alveolar (mixture of types I and II) epithelial cells were cultured on the upper surface of the ECM-coated porous membrane instead of cells of an established, tumor-derived lung epithelial cell line, as used in past lung chip studies. Using this new method, we were able to recreate a 3D cross section of a human lung alveolus composed of an alveolarcapillary interface and a vascular lumen through which human whole blood can be perfused (Figure 1c and Supplementary Figure S1 ). This improved lung alveolus chip maintained a viable epithelial-endothelial interface for >12 days under laminar flow (Figure 1d-f) , with both layers lined by cells joined via continuous intact cell-cell junctions lined by ZO-1 in the epithelium (Figure 1d ) and VE-cadherin in the endothelium (Figure 1e and Supplementary Movie S1).
Dynamic quantitative analysis of pulmonary thrombus formation in vitro
Before we initiated studies at the organ-level with the lung alveolus chip, we performed experiments to confirm that the engineered endothelium-lined tube within the lower vascular channel can be used to quantify thrombus formation under fluid shear conditions in vitro. As a positive control, we first perfused recalcified (coagulation-activated) citrated human whole blood (shear stress: 3 N m -2 ) containing fluorescent-labeled platelets through a collagen-coated lower microchannel that did not have an endothelial cell lining. As expected, 24, 25 collagen exposure led to rapid platelet adhesion to the walls of the microchannel within minutes (Figure 2a , top; Supplementary Movie S2), similarly to what is observed during hemostatic plug formation induced by vascular injury in vivo. 26 In contrast, when endothelial cells were cultured on all the surfaces of all four walls of the ECM-coated microchannel to form a hollow microvessel lined by a continuous vascular endothelium (Figure 1f and Supplementary Figure S1 ) and human whole blood was perfused through its lumen for 20 min, both platelet adhesion and thrombi formation were completely prevented in this healthy engineered microvessel ( Figure 2a , middle and Supplementary Movie S3). However, when the endothelium was stimulated with the inflammatory cytokine, tumor necrosis factor-a (TNF-a; 100 ng mL -1 ) prior to initiating blood flow, the inflamed vascular endothelium promoted rapid platelet recruitment and thrombus formation ( Figure 2a , bottom and Supplementary Movie S4), as occurs within inflamed microvessels in vivo. 27, 28 Interestingly, in contrast to the distributed fibrillar pattern of platelet-rich thrombi formed on the exposed collagen surface (Figure 2a, top) , the thrombi formed on the inflamed endothelium exhibited a distinct tear drop-like morphology (Figure 2a , bottom right). Although this unique thrombus morphology has not been observed in previous in vitro platelet adhesion studies that used collagen-coated microfluidic chambers, 24, 25 platelet aggregates have been reported to progressively grow and move downstream along the endothelial surface under flow in vivo.
29-31
Indeed, we could detect that this type of dynamic plateletendothelium binding behavior is responsible for this tear drop morphology when we performed video microscopic analysis of thrombi formation in the endothelium-lined vascular channel (Supplementary Movies S2-S4). Moreover, we observed formation of thrombi with a nearly identical tear drop shape and similar rapid platelet binding dynamics when we analyzed thrombi formation in vivo (Figure 2b and Supplementary Movie S5) in a previously described living mouse model of laserinduced thrombosis. 30, 32 Thus, these initial studies suggest that the engineered microvessel within this microfluidic chip seems to recapitulate the unique shape and platelet dynamics associated with thrombus formation in vivo, whereas this is not observed in ECM-coated microfluidic devices that are commonly used for in vitro analysis of thrombus formation under flow. 33 To quantify these dynamic binding interactions between platelets and endothelium, we applied a recently developed automated imaging program 28 in order to measure the kinetics of platelet binding along the length of the microfluidic channel, and we derived a nondimensional statistical method to arrive at a novel quantitative index of platelet binding dynamics (PBDs; Supplementary Figure S2 ; see METHODS for details). When we calculated the PBD index for platelet interactions measured on collagen under flow, we found it to be extremely low because once the platelets adhere they do not change their position ( Figure 2c , top and Figure 2d ). In contrast, when we stimulated the endothelium in the microchannel with increasing doses of TNF-a that induce a dose-dependent increase in expression of the surface adhesion molecule intercellular adhesion molecule (ICAM)-1 ( Figure 2e ), we observed a corresponding dosedependent rise in both platelet binding to the endothelium ( Figure 2c ) and in the PBD index (Figure 2d ), confirming the sensitivity of this method to detect dynamic thromboinflammatory interactions between platelets and endothelium associated with vascular inflammation. Moreover, this dynamic analytical method can distinguish platelet accumulation due to vascular injury (ECM exposure) in a healthy endothelium compared to thrombosis caused by endothelial activation by inflammatory stimuli, whereas quantitation of the average area of platelet adhesion (percentage platelet coverage relative to total area of channel) frequently used to analyze thrombosis on exposed ECM-coated substrates in vitro 25 cannot (Supplementary Figure S3 ). Additionally, we found that this PBD index increased when we raised the hemodynamic shear rate from 275 s -1 to 750 s -1 in the microfluidic channel (by altering pumping rates), indicating a higher tendency to form platelet-rich thrombi and promote platelet-endothelial binding interactions in vitro (Figure 2d ), as reported in past studies. 34, 35 In contrast, quantification of the average area of platelet adhesion 24, 25 was not sensitive to this change in shear (Supplementary Figure S3) . Finally, we used the same method to analyze a single thrombus formed in a laser-injured mouse vessel to confirm the relevance of the PBD index in a physiologically relevant in vivo model of thrombosis. Again, using the same analytical method in combination with pseudo-coloring of images to indicate the local PBD index, we confirmed that the dynamics of platelet-endothelial binding were more rapid along the boundary of the thrombus compared to its central core (Figure 2f, left) , and we observed a pattern of platelet-endothelial binding dynamics within individual thrombi that was nearly identical to that seen within thrombi that formed in our endothelium-lined microfluidic channel in vitro ( Figure  2f , right). These regional heterogeneities in thrombus dynamics have been shown to be due to the thrombus consisting of a stable core region surrounded by a reactive unstable shell, 31, 36 but, to our knowledge, they have not been previously shown in cultured living endothelium or characterized in vitro.
Inflammatory cytokine-induced pulmonary thrombosis in the human lung alveolus chip
We then explored whether we could study organ-level contributions (as opposed to endothelial tissue-level contributions alone, as done above) to vascular inflammation-driven thrombus formation using the human lung alveolus chip that contains human primary alveolar epithelium on the top of the ECM-coated membrane, closely interfaced with the human endothelium-lined vascular channel below (Figure 1 ). When we perfused fluorescent tracer dye (4 kDa dextran) through the vascular channel of alveolus chip cultured for 12 days, we found that the alveolar-capillary interface formed on-chip retained a high level of pulmonary barrier function with low permeability to the dye (Figure 3a) , confirming past results using lung chips lined by an established human A549 alveolar cell line.
20,21 Importantly, we also were able to perfuse recalcified, citrated human whole blood for up to 20 min (shear rate5 275 s -1 ) through the vascular lumen of the lung alveolus chip without producing any significant platelet adhesion or blood clotting (Supplementary Movie S6), as observed using a microfluidic system lined only by endothelium (Figure 2a , middle; Supplementary Movie S2). Direct addition of increasing doses of TNF-a to the alveolar epithelium compartment resulted in a dose-dependent increase in pulmonary vascular permeability (Figure 3a) as well as a concomitant increase in ICAM-1 expression on the endothelium below ( Figure 3b) . As expected, induction of ICAM-1 expression on the endothelium by delivery of TNF-a into the epithelial compartment of this organ-level model of an inflamed endothelium was accompanied by a dose-dependent increase in platelet-endothelial binding dynamics (Figure 3c) , as previously observed when TNF-a was infused directly through the endothelium-lined vascular channel (Figure 2d) . Thrombi formed over the entire endothelial surface within the vascular compartment of the lung alveolus chip, and they contained both platelets and fibrin by the end of the assay (Figure 3d) . Thus, this microfluidic system can effectively model the pro-inflammatory effects of TNF-a released into the epithelial compartment that lead to activation of the underlying endothelium and subsequent induction of intravascular blood thrombus formation.
LPS-induced pulmonary thrombosis is mediated by activation of the epithelium
We then tested the effects of LPS on vascular thrombus formation using the pulmonary alveolus chip because this gramnegative bacterial endotoxin has been shown to cause acute lung injury and induce pulmonary thrombosis in vivo.
37,38 When we first added LPS (100 ng mL -1 ) directly to medium flowing through the vascular channel lined by the endothelial tissue (in the absence of the alveolar epithelium) for 2 h, we could not detect any significant change in barrier permeability (Figure 4a) , endothelial junctional integrity (Figure 4b,c) , or ICAM-1 staining ( Figure 4d ) compared with untreated organ chips. Thus, LPS does not exhibit its reported ability to induce pulmonary thrombosis when analyzed at the tissue level alone (i.e., using only vascular endothelium under flow) at the dosage and time that we applied. In contrast, we observed a large increase in permeability of the tissue-tissue interface within 2 h when we added LPS to the lumen of the upper channel lined by alveolar epithelium in the lung alveolus chip (Figure 4a ). This correlated with disruption of endothelial cell-cell junctions, as demonstrated by immunofluorescence microscopic analysis of VE-cadherin (Figure 4b,c) and quantitation of the size of the gaps exposed between junctions in the endothelium (Figure 4c) , as well as endothelial activation measured by increased expression of ICAM-1 (Figure 4d) . Importantly, this also correlated with a significant increase in the PBD index in the intact lung chip treated in this manner with LPS and perfused with whole blood, whereas there was no detectable change in platelet-endothelial binding interactions in the absence of the alveolar epithelium (Figure 4e) . Additionally, we observed that large fibrin-containing platelet aggregates appeared in the vascular channel only in intact organ chips containing both the alveolar epithelium and endothelium (Figure 4f) . Furthermore, to confirm that this unique organ-level response to LPS is relevant for pulmonary thrombosis per se, we fabricated similar chips using primary human lung microvascular endothelial cells (HPMEC) instead of HUVECs in the vascular channel (Supplementary Figure S4a) . In these studies, addition of LPS to the alveolar epithelium channel produced similar activation of ICAM-1 in the human pulmonary microvascular endothelium within the vascular channel (Supplementary Figure S4b,c) .
To better characterize this organ-level response to LPS, we took advantage of our ability to collect effluent from the vascular channel of the chips and analyzed cytokine release profiles produced in the lung alveolus-on-a-chip when stimulated with LPS. Of 12 cytokines tested, only three exhibited significant elevation in response to LPS stimulation specifically when the alveolar epithelium was present: interleukin-6 (IL-6), IL-8, and monocyte chemotactic protein-1 (Figure 4f) . Thus, this tissue-tissue interaction that leads to microvascular thrombosis in this model may be mediated at least in part by IL-6, as it has been previously shown to induce ICAM-1 expression in endothelium. 39 Finally, to determine the physiological relevance of these findings, we used our automated imaging technique to analyze the effects of LPS delivered intraperitoneally on platelet-endothelial binding interactions in the mouse cremaster arteriole and vein in vivo. Quantitative imaging confirmed that intravenous injection of LPS alone was not sufficient to directly stimulate increased platelet-endothelial binding interactions in vivo in both the arteriole and the vein (Supplementary Figure S5a,b) . In contrast, when these vessels were injured with a laser, thereby releasing inflammatory factors locally, we observed an increase in both platelet-endothelial binding and intravascular thrombus formation (Supplementary Figure S5a,b) . Taken together, these findings confirm that induction of intravascular pulmonary thrombosis by LPS involves tissue-tissue interactions between the lung alveolar epithelium and vascular endothelium that lead to activation of a cytokine cascade generated by the epithelium, which induces the endothelium to become prothrombotic, as suggested by our alveolus chip studies. This insight into the role of epithelium in vascular inflammation-led alveolar thrombus formation could not have easily been made using in vivo animal models or human clinical studies. 100 lm; (a, c, d , and e) *P < 0.05; **P < 0.01; two-way analysis of variance (ANOVA)). (g) Quantification of cytokines released, as measured within the effluent of the vascular channel, showing significant differences in a subset of cytokines following 2 h of LPS stimulation compared with untreated conditions (n 5 2).
Testing of potential antithrombotic therapeutic in the human lung alveolus chip
To further explore the potential value of this model as a preclinical drug development tool, we used the primary lung alveolus chip to analyze the antithrombotic and anti-inflammatory activities of a potential drug candidate. Protease activated receptor-1 (PAR-1) has been shown to mediate tissue inflammation and hemostasis, and, therefore, it represents a potential target for the treatment of various pathologies leading to coagulation abnormalities, such as sepsis. 40 Here, we analyzed the effects of parmodulin-2 (PM2), which is a potent PAR-1 inhibitor that has been recently shown to have antithrombotic and vascular protective effects comparable to those of activated protein C when tested in both a bioengineered endothelium-lined vessel in vitro and a recently developed mouse model. 41 In platelets, PAR-1-mediated signalling is critical for platelet activation. 42 Not surprisingly, when we pre-incubated human whole blood with PM2 (30 lM) for 30 min before perfusing it through the vascular channel of an LPS-treated alveolus chip, we observed a significant reduction in platelet-endothelial binding in comparison to untreated blood (Figure 5a) . Interestingly, when we first incubated the endothelium-lined vascular channel of the lung chip with PM2 for 4 h before adding LPS to the alveolar lumen and then perfused human whole blood through the endothelial channel, we found that PM2 treatment of the endothelium significantly decreased thrombi formation (Figure 5a ) as well as pulmonary vascular leakage (Figure 5b) induced by LPS. Furthermore, pre-incubation of both the endothelium (4 h) and blood (30 min) with PM2 completely inhibited platelet binding to the endothelium and thrombus formation in the LPS-stimulated alveolus chip (Figure 5a) . Together, these studies with our model indicate that PM2 exhibits potent cytoprotective, as well as antithrombotic, activities in human acute lung dysfunction.
To validate the physiological relevance of these results, we carried out similar studies in an in vivo model of LPS-induced lung injury. 43 Intratracheal delivery of LPS (1 lg/mouse) to the airway and alveolar epithelium of a mouse (Supplementary Figure S6a) resulted in a dose-dependent increase of the vascular barrier disruption in vivo (Supplementary Figure S6b) . Notably, intravenous administration of the same dose of PM2 as used in our in vitro studies (30 lM) significantly reduced the LPSinduced injury of the alveolar tissue in vivo, as indicated by a significant improvement of vascular permeability (Supplementary Figure S6c) , thus confirming the findings we obtained using the lung alveolus chip (Supplementary Figure S6b) .
DISCUSSION
These studies demonstrate that the primary human lung alveolus chip permits visualization and quantitative real-time analysis of organ-level interactions relevant to in situ thrombus formation in human lungs. This organ chip technology allowed us to dissect contributions of various human cell types and tissues (epithelium, endothelium, and platelets), pro-inflammatory signals (TNF-a and LPS), and fluid flow, as well as a potential antithrombotic and anti-inflammatory therapeutic (PM2), which would be nearly impossible to perform in vivo. Thus, this new in vitro model of human pulmonary thrombosis offers unique capabilities that may prove useful for drug development as well as analysis of the pathophysiology of thrombotic diseases.
Although it has been recognized that whole blood rheology, mechanics, and cellular composition impact vascular biology, immune function, platelet function, and signaling pathways involved in hemostasis, [44] [45] [46] most contemporary in vitro analytical devices have not incorporated native whole blood flow in their assessment due to technical difficulties. 24, [47] [48] [49] [50] A salient feature of the pulmonary organ chip microfluidic system presented here is that it is able to perfuse human whole blood in its native state (recalcified after anticoagulation in sodium citrate) at any desirable shear rate, thereby providing a more physiologically relevant in vitro platform to study and analyze intravascular thrombo-inflammation in the lungs. Second, by harnessing the Figure 5 Therapeutic effect of a protease activated receptor-1 (PAR-1) inhibitor (parmodulin) in lung injury (a) platelet binding dynamic (PBD) index measured in the chip after blood perfusion through the vascular channel of an alveolus chip previously exposed to lipopolysaccharide (LPS; 100 ng mL -1 for 2 h) on the epithelial side, whereas the blood, the endothelium, or both were treated with parmodulin (PM2) before perfusion. (b) Vascular permeability (fluorescence normalized by untreated vascular tissue) measured inside the LPS-treated microdevice with or without treatment of PM2. (c) Vascular permeability measurements in vivo after intratracheal delivery of LPS (1 lg per mouse) for 2 h and systemic delivery of PM2 (30 lM) for 4 h (a-c, n 5 3; *P < 0.05; **P < 0.01; one-way analysis of variance (ANOVA)).
potential of modern automated fluorescence microscopy and mathematical modelling, we developed a new way to assess platelet-surface interactions over large spatiotemporal scales. Our analysis shows that the integrated interplay between platelets, thrombi, the vessel wall, and blood flow dynamics can be analyzed in this integrated system-level assay. Significantly, we showed that the pulmonary thrombus formation caused due to endothelial activation in this in vitro model correlates well with thrombosis that occurs in vivo in response to laser injury in mice, both in terms of morphology and regional heterogeneity, and as well as platelet binding dynamics. 31, 36 By incorporating primary human alveolar epithelial cells in this modified system, we overcame a limitation of the previously described lung chip that used a human lung tumor-derived alveolar epithelial cell line, 20, 21 which could exhibit prothrombotic activities and thereby complicate studies involving inflammatory activation. The coculture of this primary alveolar epithelium with human vascular endothelium inside the alveolus-chip for up to 2 weeks allowed us to highlight the critical role that alveolar epithelium plays in pulmonary thrombosis induced by LPS endotoxin. The finding that the presence of LPS in lungs does not promote thrombosis by acting directly on the endothelium would be very difficult to show in vivo in real time, as individual tissue and cellular compartments inside the organ cannot be regulated separately, and blood flow inside the lung vessels cannot be controlled or observed over large areas as we can do using the organchip technology.
However, the full potential of the current model has not yet been explored. For example, in the present study, we did not mimic lung breathing motions, which were previously shown to have important effects on lung physiology (e.g., surfactant production, absorption of nanoparticulates, and induction of pulmonary edema by IL-2), 20, 21 and which also could potentially influence pulmonary thrombosis. Another potential caveat is that we used HUVECs, not lung-specific endothelial cells, in most of our studies; however, when we replaced them with primary human microvascular endothelial cells in our LPS stimulation experiments, we obtained nearly identical results and similar findings were reported using HUVECs and lung microvascular endothelium in prior lung-chip studies. 20 We did not analyze the role of immune cells (e.g., neutrophils) in this study for simplicity and to accommodate high-speed imaging with fewer fluorescent channels, but this could be done in future studies as shown in past work with the human organ chips. 19, 20 Nevertheless, this primary human lung alveolus chip methodology allowed us to recapitulate many features of vascular thrombosis in vitro that have only previously been observed in vivo. Notably, we were able to dissect the significance of alveolar epithelium in the onset and propagation of platelet function and thrombosis in acute lung injury. It also allowed us to unravel the cytoprotective and antithrombotic effects of a novel PAR-1 antagonist in the setting of acute lung injury and whole blood perfusion. Thus, this human pulmonary alveolar chip model may offer a new tool for preclinical testing of antithrombotic drugs that can potentially detect their unwanted thrombotic side effects before they enter human clinical trials. This system also can be used to study fundamental mechanisms of hemostasis regulation in a more physiologically relevant organ-level context. Finally, this tool could offer a new method for a personalized assessment of drug responses to therapy, as well as potential toxicities, by obtaining lung cells (e.g., from biopsies or using lung cells differentiated from induced pluripotent stem cells) and blood from the same patient, and thereby help to individualize therapeutic regimens in the future.
METHODS
Materials and Methods are available in Supplementary Information.
Additional Supporting Information may be found in the online version of this article.
